Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

This study has been completed.
Information provided by:
Bayer Identifier:
First received: April 15, 2009
Last updated: May 28, 2012
Last verified: May 2012
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.

Condition Intervention
Multiple Sclerosis
Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Betaferon Treatment and Exercise Data Gathering IN Early MS

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Physical Activity and Fatigue [ Time Frame: At baseline and at Month 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Health-related Quality of Life [ Time Frame: At baseline and at Month 24 ] [ Designated as safety issue: No ]
  • Depression [ Time Frame: At baseline and at Month 24 ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Enrollment: 1739
Study Start Date: August 2006
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Intravenous therapy according to product information


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients after a first demyelinating event suggestive of MS as well as patients with recently diagnosed RRMS (< 12 months)

Inclusion Criteria:

  • Multiple sclerosis diagnosed within the last 12 months
  • Clinically isolated Syndrome (CIS), under Interferon-beta-1b treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00882453

  Show 33 Study Locations
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Regional Medical Director, Bayer Healthcare AG Identifier: NCT00882453     History of Changes
Other Study ID Numbers: 13853  BF0601  310721 
Study First Received: April 15, 2009
Last Updated: May 28, 2012
Health Authority: Australia: Human Research Ethics Committee
Belgium: Ethics Committee
Canada: Ethics Review Committee
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
France: Comité National de l'Ordre des Médecins = CNOM
Germany: Federal Institute for Drugs and Medical Devices
Greece: Ethics Committee
Greece: National Organization of Medicines
Israel: Ethics Commission
Italy: Ethics Committee
Kazakhstan: National Center for Expertise of Medicinal Drugs
Lebanon: Institutional Review Board
Mexico: Ethics Committee
Norway:National Committee for Medical and Health Research Ethics
Portugal: National Committee for Data Protection (CNPD)
Portugal: Health Ethic Committee
Portugal: National Pharmacy and Medicines Institute
South Korea: Korea Food and Drug Administration (KFDA)
Slovenia: Ethics Committee
Slovenia: Agency for Medicinal Products - Ministry of Health
Spain: Regional Health Authorities
Spain: Ethics Committee
Spain: Spanish Agency of Medicines
Sweden: Regional Ethical Review Board
Taiwan: Institutional Review Board
Taiwan: Local Ethics Committees
Thailand: Ethical Committee
United Kingdom: National Health Service
United Kingdom: Research Ethics Committee

Keywords provided by Bayer:
Physical Activity

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs processed this record on December 09, 2016